NPWR Investors Have Opportunity to Lead NET Power Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NET Power Inc. ('Net Power' or 'the Company') (NYSE: NPWR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between June 9, 2023 and March 7, 2025, inclusive (the 'Class Period'), are encouraged to contact the firm before June 17, 2025.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Net Power was unlikely to complete Project Permian on time and on budget due to supply chain issues and multiple issues specific to the site and region. The Company's projections about the time and financial resources required to complete Project Permian were not based in reality. The Company's financial results and business would be negatively impacted by the delays and cost overruns associated with Project Permian. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Net Power, investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Upturn

27 minutes ago

• Business Upturn

NurExone Advances U.S. Growth Strategy with Acceptance into Prestigious ARMI HealthTech Hub Accelerator and Provides Corporate Update

By GlobeNewswire Published on June 20, 2025, 11:30 IST TORONTO and HAIFA, Israel, June 20, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ('NurExone' or the 'Company'), a biotech company developing exosome-based therapies for central nervous system injuries, announced today that it has been accepted into the HealthTech Hub ('HTH') Accelerator Program. Based in Boston, Massachusetts, home to more than 1,000 biotech companies1, HTH is operated by the Advanced Regenerative Manufacturing Institute ('ARMI') and its BioFabUSA initiative. NurExone's acceptance into the prestigious HTH Accelerator Program will support the Company's expansion into the U.S. market following the establishment of Exo-top Inc. ('Exo-TOP'), the Company's wholly owned U.S. subsidiary dedicated to GMP-compliant exosome manufacturing for clinical development and commercial scale-up. HTH, co-led by ARMI and Mass General Brigham, is a competitive accelerator program supported by the U.S. Department of Health and Human Services and Israel's Ministry of Health. The HTH Accelerator Program selects a limited number of innovative companies each year to help them validate U.S. clinical relevance, strengthen commercialization strategies, and build meaningful collaborations with key stakeholders across the U.S. HealthTech landscape. The program is funded by HTH at no cost to participants. Dr. Lior Shaltiel, CEO of NurExone, commented: 'The HTH Acceleration Program offers the kind of U.S.-based insight and guidance needed at this stage of our growth. As we establish Exo-TOP to manufacture clinical-grade exosomes in the U.S., the HTH will help us sharpen our regulatory and scale-up strategies and pursue meaningful commercial collaboration opportunities. This is a timely and strategic opportunity to accelerate our commercialization pathway in the world's largest healthcare market 2 .' NurExone's participation in the HTH Accelerator Program is expected to enhance its visibility within the U.S. regenerative medicine ecosystem and to support its mission to bring novel exosome-based therapeutics to patients with unmet needs. Omnibus Plan Approval The Company is pleased to announce that, further to its press release dated June 4, 2025, at the Company's annual general and special meeting held on June 18, 2025 (the 'Meeting'), disinterested shareholders ratified and approved the amended and restated omnibus incentive plan (the 'Omnibus Plan'), a copy of which is available under the Company's SEDAR+ profile at The Omnibus Plan is a hybrid plan that provides flexibility to grant-equity incentive awards in the form of stock options ('Options'), restricted shares ('Restricted Shares') and restricted share units ('RSUs'). The Omnibus Plan is a hybrid 10% rolling and 10% fixed share-based compensation plan that amends and restates the Company's previous equity incentive plan approved by shareholders on June 4, 2024 (the 'Previous Plan'). The Previous Plan was a 20% fixed share-based compensation plan whereby the maximum number of common shares in the capital of the Company ('Common Shares') reserved for issuance was set at 13,166,085, representing 20% of the issued and outstanding Common Shares as of the effective date. The Omnibus Plan now includes (i) a 10% 'rolling' Option component that shall not exceed 10% of the Company's total issued and outstanding Common Shares from time to time; and (ii) a 10% fixed component permitting up to 7,800,781 RSUs and Restricted Shares in the aggregate. Additionally, the Omnibus Plan was amended to increase the number of securities issuable to insiders of the Company. The Previous Plan provided, that unless approved by disinterested shareholders, (i) the maximum number of securities issuable to insiders collectively would not exceed 10% of the Company's securities at any time and (ii) the maximum number of securities issuable to insiders collectively in any twelve-month period would not exceed 10% of the Company's total issued and outstanding securities as at the date any award was granted to an insider. Now, the Omnibus Plan provides the following that (i) the maximum number of the Company's securities issuable to insiders collectively shall not exceed 20% of the Company's total issued and outstanding Common Shares at any point in time and (ii) the maximum number of the Company's securities issuable to insiders collectively, in any 12-month period, when combined with all of the Company's other share compensation arrangements, shall not exceed 20% of the Company's total issued and outstanding securities, calculated as at the date any award is granted or issued to any insider. RSU Grants In addition, the Company announced that it has granted an aggregate of 1,125,000 RSUs to certain officers and directors of the Company pursuant to the terms and conditions of the Omnibus Plan. Each RSU vests on the one-year anniversary of the grant date and may be settled, upon their vesting, into one Common Share. The RSUs and underlying Common Shares are subject to the Exchange Hold Period (as such term is defined under the policies of the TSX Venture Exchange ('TSXV')). About NurExone NurExone Biologic Inc. is a TSXV, OTCQB, and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury, both multi-billion-dollar marketsi. Regulatory milestones, including obtaining the Orphan Drug Designation, facilitates the roadmap towards clinical trials in the U.S. and Europe. Commercially, the Company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. NurExone has established Exo-Top Inc., a U.S. subsidiary, to anchor its North American activity and growth strategy. For additional information and a brief interview, please watch Who is NurExone?, visit or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube. For more information, please contact: Dr. Lior ShaltielChief Executive Officer and DirectorPhone: +972-52-4803034 Email: [email protected] Dr. Eva Reuter Investor Relations – GermanyPhone: +49-69-1532-5857 Email: [email protected] Allele Capital Partners Investor Relations – +1 978-857-5075 Email: [email protected] FORWARD-LOOKING STATEMENTS This press release contains certain 'forward-looking statements' that reflect the Company's current expectations and projections about its future results. Wherever possible, words such as 'may', 'will', 'should', 'could', 'expect', 'plan', 'intend', 'anticipate', 'believe', 'estimate', 'predict' or 'potential' or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to: the; the Company's acceptance into the prestigious HTH Accelerator Program will support the Company's expansion into the U.S. market; the Company's participation in the HTH Accelerator Program is expected to enhance its visibility within the U.S. regenerative medicine ecosystem and support its mission as discussed herein; each RSU will be settled into one Common Share; and the NurExone platform technology offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications, including recovery of optic nerve function and overall visual health. These statements reflect management's current beliefs and are based on information currently available to management as at the date hereof. In developing the forward-looking statements in this press release, we have applied several material assumptions, including: the Company's acceptance into the prestigious HTH Accelerator Program will allow it to support the Company's expansion into the U.S. market; the Company's participation in the HTH Accelerator Program will give the Company the ability to enhance its visibility within the U.S. regenerative medicine ecosystem and support its mission as discussed herein; each RSU will be settled into one Common Share; and the NurExone platform technology offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications, including recovery of optic nerve function and overall visual health Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to risks related to: the Company's early stage of development; lack of revenues to date; government regulation; market acceptance for its products; rapid technological change; dependence on key personnel; dependence on the Company's strategic partners; the fact that preclinical drug development is uncertain, and the drug product candidates of the Company may never advance to clinical trials; the fact that results of preclinical studies and early-stage clinical trials may not be predictive of the results of later stage clinical trials; the uncertain outcome, cost, and timing of product development activities, preclinical studies and clinical trials of the Company; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; the inability to obtain or maintain regulatory approval of the drug product candidates of the Company; the introduction of competing drugs that are safer, more effective or less expensive than, or otherwise superior to, the drug product candidates of the Company; the initiation, conduct, and completion of preclinical studies and clinical trials may be delayed, adversely affected or impacted by unforeseen issues; the inability to obtain adequate financing; the inability to obtain or maintain intellectual property protection for the drug product candidates of the Company; risks that the Company's intellectual property and technology won't have the intended impact on the Company and/or its business; the Company's inability to carry out its pre-clinical trials and realize upon the stated benefits of the pre-clinical trials; the inability of the Company to realize on the benefits of exosomes; the inability of the Company to produce and/or supply exosomes for a wide range of applications; the inability of the Company's products to be used for patient treatment; there not being broader adoption in the field and/or cell therapy applications; the inability of the Company to fulfill its intended future plans and expectations; there not being growing clinical demand for innovative treatments in spinal cord, optic nerve, and/or other therapeutic areas; the Company's inability to realize upon the stated potential for exosome-loaded drugs in regenerating or repairing damaged nerves; the Company's inability to maintain its ongoing commitment to using its ExoTherapy platform to advance the field of regenerative medicine and/or cell therapy applications; the Company's inability to expand into further studies; the Company will not receive all required regulatory approvals; the Company will not have clinical and/or commercial breakthroughs in regenerative medicine; the Company will be unable to enhance its presence in key markets; the NurExone platform technology not offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications; the Company will not realize its future development plans, operational initiatives, and strategic objectives; the Company will not advance its therapeutic programs and clinical milestones; the Company will not engage with regulatory agencies; the Company's acceptance into the prestigious HTH Accelerator Program will not support the Company's expansion into the U.S. market; the Company's participation in the HTH Accelerator Program will not enhance its visibility within the U.S. regenerative medicine ecosystem and will not support its mission as discussed herein; each RSU will not be settled into one Common Share; and the risks discussed under the heading 'Risk Factors' on pages 44 to 51 of the Company's Annual Information Form dated August 27, 2024, a copy of which is available under the Company's SEDAR+ profile at . These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law. Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. i Spinal cord injury, Glaucoma 1 2 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.

Hamilton Spectator

2 hours ago

• Hamilton Spectator

Parliament set to rise today, with MPs to vote on controversial major projects bill

OTTAWA - Prime Minister Mark Carney's major projects and internal trade bill will be voted on today before the House of Commons rises until September. A closure motion the government passed to limit debate says the House won't adjourn today until debate wraps up on Bill C-5 and it clears the chamber. The Liberal government's controversial legislation, which would let cabinet quickly grant federal approvals for big industrial projects like mines, ports and pipelines, sailed through committee in the early hours of Thursday with support from the Conservatives. Indigenous and environmental groups and some opposition MPs and senators have criticized the government for rushing a bill through Parliament that gives cabinet such sweeping powers. The legislation was amended Thursday to withdraw the power it gave cabinet to sidestep the Indian Act after weeks of criticism from First Nations leaders. As Canada continues to grapple with U.S. tariffs, Carney on Thursday called C-5 called the 'core' of Canada's domestic economic response. A Senate programming motion has the upper chamber wrapping up its examination of Bill C-5 by June 27. — With files from Kyle Duggan and Alessia Passafiume This report by The Canadian Press was first published June 20, 2025. Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .

Business Wire

5 hours ago

• Business Wire

Combined Shareholders' Meeting of June 19, 2025: All Submitted Resolutions Were Adopted

NEUILLY-SUR-SEINE, France--(BUSINESS WIRE)--The Combined Shareholders' Meeting of Bureau Veritas (the "Company"), chaired by Mr. Laurent Mignon, Chairman of the Board of directors, was held today at the Company's head office. All resolutions submitted to the Shareholders' Meeting were adopted at a large majority, including: The approval of the statutory and consolidated financial statements for the financial year ending on December 31, 2024, and the approval of a dividend distribution of €0.90 per share to be paid in cash on July 3, 2025 (ex-date on July 1, 2025) on positions closed on July 2, 2025; The approval of a related-party agreement concerning the Company's participation in Wendel's share placement (acquisition by the Company of its own shares); The approval of the report on Corporate Officers' compensation; The approval of fixed, variable and extraordinary components of the total compensation and benefits-in-kind paid or awarded for the 2024 financial year to Mr. Laurent Mignon, in his capacity as Chairman of the Board of Directors; The approval of fixed, variable and extraordinary components of total compensation and benefits-in-kind paid or awarded for the 2024 financial year to Mrs. Hinda Gharbi, in her capacity as Chief Executive Officer; The approval of the compensation policy for the Directors, the Chairman of the Board of Directors and the Chief Executive Officer for 2025; The authorization granted to the Board of Directors to trade in the Company's ordinary shares; The delegations and/or financial authorizations granted to the Board of Directors. The Shareholders' Meeting renewed the term of office as Director of Mr. Laurent Mignon, and the Board of Directors reappointed him as Chairman of the Board of Directors. The Shareholders' Meeting also renewed the terms of office as Directors of Ms. Julie Avrane, Ms. Ana Giros Calpe and Mr. Jérôme Michiels. Ms. Lucia Sinapi-Thomas is leaving the Board, as her term of office has expired. The Directors commended her contribution to the Board's discussions and decisions, as well as to the work of its Committees. To replace Ms. Sinapi-Thomas, the Shareholders' Meeting appointed Ms. Elodie Perthuisot as an independent director for a term of four years. Elodie Perthuisot is a member of the Carrefour Group's Executive Committee and currently heads Carrefour Spain, one of the group's main subsidiaries. Holding an engineering degree from the École Polytechnique, she began her career in the public sector - she notably headed the office of Frédéric Mitterrand, Minister of Culture and Communication - before joining the retail sector, leading the commercial management and multichannel transformation of Fnac and then Fnac Darty. She joined Carrefour in 2018 where she has successively led the marketing in France, e-commerce and, since 2021, the group's digital and technological transformation. Under her leadership, Carrefour has significantly accelerated its digital and data ambitions, becoming a company recognized for its progress in these areas. The Bureau Veritas Board of Directors will be able to rely on her diverse experience, and in particular on her expertise in digital transformation and operational management. In the activity reports, Mrs. Hinda Gharbi, Chief Executive Officer, and Mr. François Chabas, Chief Financial Officer, presented the 2024 highlights, the 2024 financial results, providing specific details on revenue, adjusted operating profit, net earnings per share, cash flow statement and the financial position. Mrs. Hinda Gharbi, Chief Executive Officer, then presented the review of the Group's activities for the 2024 financial year, and detailed the first quarter revenue as well as the 2025 outlook. She also provided an update on the LEAP I 2028 strategic plan. Mr. Laurent Mignon and Mr. Pascal Lebard, Lead Independent Director, respectively presented corporate governance and compensation components of the Directors, the Chairman of the Board of directors and the Chief Executive Officer in 2024, as well as the compensation policies. The broadcast of the Shareholders' Meeting, including the full presentation and the complete results of the vote of the resolutions, will be available on the Company's website ( ABOUT BUREAU VERITAS Bureau Veritas is a world leader in inspection, certification, and laboratory testing services with a powerful purpose: to shape a world of trust by ensuring responsible progress. With a vision to be the preferred partner for customers' excellence and sustainability, the company innovates to help them navigate change. Created in 1828, Bureau Veritas' 84,000 employees deliver services in 140 countries. The company's technical experts support customers to address challenges in quality, health and safety, environmental protection, and sustainability. Bureau Veritas is listed on Euronext Paris and belongs to the CAC 40, CAC 40 ESG, SBF 120 indices and is part of the CAC SBT 1.5° index. Compartment A, ISIN code FR 0006174348, stock symbol: BVI. For more information, visit and follow us on LinkedIn. Our information is certified with blockchain technology. Check that this press release is genuine at